News Search Results
May 26, 2026, 07:30 ET Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
developing HyBryte™ (SGX301 or synthetic hypericin sodium), a photodynamic therapy utilizing visible light, for the treatment of cutaneous T-cell lymphoma (CTCL) in a Phase 3 study called "FLASH2" (Fluorescent Light Activated Synthetic Hypericin 2). The Data Monitoring Committee completed its interim
More news about: SOLIGENIX, INC.
May 26, 2026, 07:30 ET Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
May 24, 2026, 20:47 ET From Pakistan to Shanghai: A CAR-T Journey Fighting Relapsed Lymphoma
treatments for aggressive recurrent blood cancer. Muhammad, a hospital staff member from Quetta, Pakistan, suffered from diffuse large B-cell lymphoma (DLBCL). After multiple chemotherapy courses and a failed bone marrow transplant, his disease progressed to Stage IVB by early 2026, with widespread
More news about: Jiahui Health
May 24, 2026, 20:36 ET From Pakistan to Shanghai: A CAR-T Journey Fighting Relapsed Lymphoma
treatments for aggressive recurrent blood cancer. Muhammad, a hospital staff member from Quetta, Pakistan, suffered from diffuse large B-cell lymphoma (DLBCL). After multiple chemotherapy courses and a failed bone marrow transplant, his disease progressed to Stage IVB by early 2026, with widespread
More news about: Jiahui Health
May 22, 2026, 17:21 ET Keller Postman Removes Roundup Missouri Class Case to the U.S. District Court for the Eastern District of Missouri and Objects to the Case on Behalf of Absent Class Members
over 21 years. Residential users of Roundup who developed cancer are capped at $40,000 in gross recoveries. Each victim suffers from non-Hodgkin lymphoma, a type of blood cancer, caused by exposure to Roundup.
More news about: Keller Postman LLC
May 22, 2026, 08:00 ET Parker Institute for Cancer Immunotherapy Brings the Power of Its Integrated Network to ASCO 2026
Outcomes (David Miklos, MD, PhD — Stanford): Long-term real-world outcomes of axicabtagene ciloleucel in relapsed/refractory large B-cell lymphoma (Abstract 7028).About the Parker Institute for Cancer Immunotherapy (PICI) The Parker Institute for Cancer Immunotherapy
More news about: Parker Institute for Cancer Immunotherapy
May 21, 2026, 22:40 ET 【2026 ASCO】亞盛醫藥公佈多項臨床進展，三項獲快速口頭報告
open-label, randomized, phase 3 registrational study of lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress利沙托克拉（APG-2575）治療既往經治慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者的全球
More news about: 亞盛醫藥
May 21, 2026, 20:00 ET Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
total of 413 patients with previously untreated locally advanced or metastatic NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alterations and with programmed death ligand 1 (PD-L1) positive (defined as tumor proportion score (TPS) ≥1%), covering both squamous
More news about: Kelun-Biotech
May 21, 2026, 18:45 ET What drives multimillion-dollar medical claims? Sun Life report shows secondary health conditions, hospital stays and specialty drugs among key factors
therapy that slows the progression of Duchenne muscular dystrophy.The highest multimillion-dollar claims were for blood cancers (leukemia/lymphoma/myeloma), with an average of $5.45 million in 2025; the highest claim for a single leukemia patient in 2025 was nearly $8 million.Impact
More news about: Sun Life U.S.
May 21, 2026, 17:30 ET Rutgers Cancer Institute and RWJBarnabas Health to Highlight Advances Shaping the Future of Cancer Research at the 2026 ASCO Annual Meeting
of the Phase 3 OLYMPIA-3 study evaluating odronextamab (ODRO) plus Chemotherapy (CHOP) in patients with previously untreated diffuse large B-cell lymphoma with high-risk features. Among 40 patients randomized to two dosing regimens, the safety profile was generally manageable and similar across groups.
More news about: Rutgers Cancer Institute and RWJBarnabas Health
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.Adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This
More news about: Eli Lilly and Company
May 21, 2026, 11:52 ET New study could improve testing and treatment for rare brain, spinal cord, and eye cancers
https://doi.org/10.1093/clinchem/hvag036Primary central nervous system lymphoma (PCNSL), a rare cancer that affects the brain, spinal cord, or eyes, has one of the poorest prognoses among cancers that originate in white blood
More news about: Association for Diagnostics & Laboratory Medicine (ADLM)
May 21, 2026, 10:00 ET Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
oral fourth-generation BTK inhibitor, against pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) who have received prior therapy with a covalent BTK inhibitor (cBTKi). Existing BTK inhibitors face resistance challenges, underscoring
More news about: Lupeng Pharmaceutical Ltd
May 20, 2026, 05:20 ET Through the America's Most Artistic Kid Competition, Colossal Raises $1.6 Million While Celebrating the Next Gen of Creative Visionaries
$1,665,882 to support people impacted by blood cancer.These funds will help advance the mission of Blood Cancer United (formerly The Leukemia & Lymphoma Society) to cure blood cancers and improve the quality of life for patients and their families. From funding lifesaving research to supporting pediatric
More news about: Colossal
May 19, 2026, 09:30 ET Funding from Patients, Caregivers, Foundations and Industry Partners Fuels ALK-positive Research
loved ones, industry partners and medical leaders, is funding two $300,000 two-year awards to accelerate treatment options for people with anaplastic lymphoma kinase (ALK) fusion-driven non-small cell lung cancer (NSCLC.)
More news about: Lung Cancer Research Foundation
May 19, 2026, 09:00 ET Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
https://www.biopharmadive.com/news/nkarta-leukemia-lymphoma-nk-cell-therapy-results/622594/ [7]
More news about: Equity Insider
May 18, 2026, 15:43 ET Unleashed Brands Foundation Donates $200,000 to Blood Cancer United in Support of Pediatric Blood Cancer Patients & Their Families
UnleashedBrands.com.About Blood Cancer United®Blood Cancer United® (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. Since their founding in 1949, the organization
More news about: Unleashed Brands
May 18, 2026, 10:30 ET Cancer Biomarkers Market worth $54.48 billion by 2032 | MarketsandMarkets™
largest share within the cancer type segment in 2026.The market for cancer biomarkers is divided into categories by cancer type: non-Hodgkin lymphoma, kidney cancer, bladder cancer, thyroid cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, and other cancer
More news about: MarketsandMarkets
May 18, 2026, 08:05 ET FDA Approves IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi), First Biosimilars to Simponi® (golimumab) and Simponi Aria® (golimumab); Accord BioPharma to Lead U.S. Commercialization
latent TB test is negative. Lymphoma and other
More news about: Accord BioPharma
May 15, 2026, 16:30 ET Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
malignancies;LYMPHIR administered prior to commercial CD19-directed CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with positive topline safety and efficacy results; and,Continued FDA engagement on Mino-Lok®, an antibiotic lock solution
More news about: Citius Pharmaceuticals, Inc.
May 15, 2026, 16:30 ET Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
malignancies;Phase 1 trial of LYMPHIR administered prior to CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with positive topline safety and efficacy results; and,Initiated evaluation of new bulk drug substance (BDS) suppliers
More news about: Citius Oncology, Inc.
May 14, 2026, 16:10 ET VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q® Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone
More news about: VolitionRx Limited
May 14, 2026, 13:08 ET Hematology Diagnostics Market Expected to Reach US$ 7.6 Billion by 2030, Growing at 6.4% CAGR: Wissen Research
critical roles in improving the detection of abnormal cells, workflow, and efficiency in laboratories.Rising cases of anaemia, leukaemia, lymphoma, and infections have prompted health facilities to purchase advanced haematology testing equipment to detect these diseases early and accurately. Besides,
More news about: Wissen Research LLC
May 12, 2026, 22:33 ET 【EHA2026】亞盛醫藥17項臨床進展入選2026年歐洲血液學協會年會
01:45（北京時間）第一作者：陳蘇寧教授，蘇州大學附屬第一醫院CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY一項關鍵II期臨床研究中利沙托克拉（APG-2575）治療的慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者基線特徵與預後的相關性
More news about: 亞盛醫藥
May 12, 2026, 16:00 ET Curis Provides First Quarter 2026 Business Update
Operational HighlightsTakeAim LymphomaEmavusertib is currently undergoing testing in combination with the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib in the TakeAim Lymphoma Phase 1/2 open-label, single arm expansion trial in patients
More news about: Curis, Inc.